EZH2 and rhabdomyosarcoma: To test this approach, we carried out a proof-of-concept study using EZH2 as a target for knockout in SMARCB1-negative (G-401) MRT cell line and SMARCB1-wild type (RD) rhabdomyosarcoma cell line; the former but not latter are sensitive to inhibition of EZH2 [6, 7, 23].